导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.32% | 2117/4773 |
| 近一周 | -3.22% | 3910/5462 |
| 近一月 | -9.65% | 4797/5421 |
| 近一季 | -17.64% | 4593/5209 |
| 近半年 | -2.18% | 1805/4920 |
| 近一年 | 6.28% | 1482/4366 |
| 近两年 | 108.08% | 506/2954 |
| 近三年 | 58.12% | 468/2253 |
| 成立以来 | 147.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.26% 2209/4961 |
32.36% 989/5312 |
- - |
- - |
| 2025 | 53.13% 395/4813 |
-0.68% 2351/3635 |
2.99% 1219/4076 |
49.40% 340/4524 |
0.21% 2133/4813 |
| 2024 | 7.65% 1639/3463 |
-6.09% 2005/2808 |
-4.56% 1525/3014 |
21.98% 518/3129 |
-1.54% 1743/3463 |
| 2023 | -24.69% 1972/2656 |
-3.75% 2086/2280 |
-7.73% 1899/2385 |
-10.52% 2005/2515 |
-5.23% 1294/2655 |
| 2022 | -26.10% 1366/2207 |
-17.64% 1232/1919 |
8.61% 346/2016 |
-16.13% 1404/2113 |
-1.51% 1709/2208 |
| 2021 | 12.40% 384/1822 |
-7.50% 1063/1255 |
27.53% 60/1330 |
-5.62% 836/1466 |
0.95% 1036/1822 |
| 2020 | 80.46% 41/1250 |
11.51% 15/1028 |
34.94% 20/1067 |
2.85% 997/1164 |
16.60% 158/1184 |
| 2019 | 49.31% 106/1092 |
30.76% 230/739 |
-5.76% 478/788 |
9.11% 57/850 |
11.05% 83/918 |
| 2018 | -19.70% 175/834 |
- - |
-1.68% 53/631 |
-5.17% 365/660 |
-5.97% 41/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 长城创业板指数增强A VS. 长安沪深300非周期A(740101) |